期刊文献+

肝纤维化大鼠TGF-β_1与TIMP-1 mRNA的表达及补肾柔肝方的治疗作用 被引量:9

Expression of TIMP-1 and TGF-β_1 mRNA in hepatic fibrosis rats and the therapeutic effects of Bushen Rougan Recipe
在线阅读 下载PDF
导出
摘要 目的 :探讨中药复方补肾柔肝方对二甲基亚硝胺 (dimethylnitrosamine ,DMN)诱导大鼠肝纤维化后肝脏组织金属蛋白酶抑制因子 1(tissueinhibitorofmetalloproteinase 1,TIMP 1)和转化生长因子β1(transforminggrowthfactor beta 1,TGF β1)的影响 ,以了解其对肝纤维化的治疗作用和分子机制。方法 :雄性Wistar大鼠 4 0只 ,随机分为正常对照组、模型组和治疗组 ,对模型组和治疗组运用DMN诱导大鼠肝纤维化。治疗组在造模 4周后给予补肾柔肝方灌胃 ,剂量 10 g·kg 1·d 1,共治疗 4周。第 8周末处死全部大鼠 ,对肝组织进行HE和天狼猩红染色观察 ,并采用RT PCR半定量方法 ,检测大鼠肝组织TIMP 1及TGF β1mRNA的表达水平。结果 :肝组织病理学研究结果显示DMN可以成功诱导大鼠肝纤维化 ,模型组肝组织TIMP 1和TGF β1mRNA表达明显增强 ,中药复方治疗组与模型组相比明显减弱 ,而正常对照组表达较少。结论 :TIMP 1与TGF β1mRNA的表达与肝纤维化的发生密切相关 ,中药复方补肾柔肝方对肝纤维化大鼠肝组织TIMP 1及TGF β1具有明显的抑制作用 。 Objective:To study the expression of TIMP-1 and TGF-β 1 mRNA in hepatic fibrosis rats and the therapeutic effects of Bushen Rougan Recipe (BSRGR). Methods:Hepatic fibrosis was induced in rats by dimethylnitrosamine (DMN). The rats' hepatic tissue was studied by HE staining and Sirius red staining. The rats were divided into normal control group, fibrosis model group and BSRGR treated group (10g·kg -1·d -1, i.g. for 4 weeks). At last, TIMP-1 and TGF-β 1 mRNA were detected by RT-PCR.Results:Pathological study showed that hepatic fibrosis was successfully induced by DMN in rats. The expression quantity of TIMP-1 and TGF-β 1 mRNA were the most in the fibrosis model group, the second in the BSRGR treated group,and the least in the normal control group.Conclusion: The expression of TIMP-1 and TGF-β 1mRNA was increased in the hepatic fibrosis rats, and this is one possible mechanism of hepatic fibrosis. BSRGR can inhibit the advancement of hepatic fibrosis.
出处 《中西医结合学报》 CAS 2004年第4期274-277,共4页 Journal of Chinese Integrative Medicine
关键词 肝纤维化 大鼠 TGF-Β1 TIMP-1 mRNA表达 补肾柔肝方 治疗 中医药疗法 二甲基亚硝胺 金属蛋白酶抑制因子1 转化生长因子Β hepatic fibrosis Bushen Rougan Recipe dimethylnitrosamine TIMP-1 TGF-β 1
  • 相关文献

参考文献13

  • 1[1]Friedman SL. Molecular mechanisms of hepatic fibrosis and prin ciples of therapy[J]. J Gastroenterol, 1997,32(3):424-430.
  • 2[2]Lamireau T, Desmouliere A, Bioulac-Sage P,et al. Mechanisms of hepatic fibrogenesis[J]. Arch Pediatr, 2002,9 (4): 392-405.
  • 3[3]Housset C, Guechot J. Hepatic fibrosis: physiopathology and bi ological diagnosis[J]. Pathol Biol( Paris), 1999,47(9):886-894.
  • 4[4]Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy[J]. Clin Liver Dis, 2001,5(2) :315-334.
  • 5[5]Levy MT, McCaughan GW, Marinos G, et al. Intrahepatic expression of the hepatic stellate cell marker fibrohlast activation protein correlates with the degree of fibrosis in hepatitis C virus infection[J]. Liver ,2002,22(2):93 101.
  • 6[6]Liu P,Liu CH, Wang HN, et al. Effect of salvianolic acid Bon collagen production and mitogen-activated protein kinase activity in rat hepatic stellate cells[J]. Acta Pharmacol Sin ,2002,23(8):733-738.
  • 7[7]Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond[J]. Hepatology,2000,31(1):241-246.
  • 8[8]Inuzuka S, Ueno T, Torimura T, et al. The significance of co localization of plasminogen activator inhibitor-1 and vitronection in hepatic fibrosis[J]. Scand J Gastroenterol, 1997,32(10):1052-1060.
  • 9张杰,徐列明.中医药治疗实验性肝纤维化作用机制研究进展[J].中西医结合学报,2003,1(2):142-145. 被引量:20
  • 10[10]Kahari VM, Chen YQ, Su MW, et al. Tumor necrosis factoralpha and interferon garmma suppress the activation of human type Ⅰ collagen gene expression by transforming growth factorbeta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels[J]. J Clin Invest,1990,86(5): 1489-1495.

二级参考文献69

共引文献170

同被引文献96

引证文献9

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部